Hormone replacement therapy may preserve lung function during reproductive aging

Conclusions: Female sex hormones are important for the preservation of lung function in middle aged women. The accelerated lung function decline with menopause is likely caused by decreasing estrogen levels.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Epidemiology Source Type: research

Related Links:

AbstractMenopause predisposes women to osteoporosis due to declining estrogen levels. This results in a decrease in bone mineral density (BMD) and an increase in fractures. Osteoporotic fractures lead to substantial morbidity and mortality, and are considered one of the largest public health priorities by the World Health Organization (WHO). It is therefore essential for menopausal women to receive appropriate guidance for the prevention and management of osteoporosis. The Women ’s Health Initiative (WHI) randomized controlled trial first proved hormonal therapy (HT) reduces the incidence of all osteoporosis-related ...
Source: Osteoporosis International - Category: Orthopaedics Source Type: research
Conclusions: In this cohort of women with elevated risk, high serum 25(OH)D levels and regular vitamin D supplement use were associated with lower rates of incident, postmenopausal breast cancer over 5 y of follow-up. These results may help to establish clinical benchmarks for 25(OH)D levels; in addition, they support the hypothesis that vitamin D supplementation is useful in breast cancer prevention. https://doi.org/10.1289/EHP943 About This Article Received: 09 August 2016 Revised: 23 January 2017 Accepted: 06 February 2017 Published: 06 July 2017 Address correspondence to C. R. Weinberg, 111 TW Alexander Dr., Rese...
Source: EHP Research - Category: Environmental Health Authors: Tags: Research Source Type: research
Oral osteoporosis therapy was associated with improvements in event-free survival and distant disease-free survival in post-menopausal women with breast cancer receiving adjuvant aromatase inhibitor therapy.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Tags: Breast Cancer News Source Type: news
Authors: Parish SJ, Gillespie JA Abstract This review describes the evolving role of oral hormone therapy (HT) for treating menopausal symptoms and preventing osteoporosis, focusing on conjugated estrogens/bazedoxifene (CE/BZA). Estrogens alleviate hot flushes and prevent bone loss associated with menopause. In nonhysterectomized women, a progestin should be added to estrogens to reduce the risk of endometrial cancer. Use of HT declined since the Women's Health Initiative (WHI) studies showed that HT does not prevent coronary heart disease (CHD) and that conjugated estrogens/medroxyprogesterone acetate increased th...
Source: Postgraduate Medicine - Category: Internal Medicine Tags: Postgrad Med Source Type: research
CONCLUSIONS: Women with intolerable menopausal symptoms may wish to weigh the benefits of symptom relief against the small absolute risk of harm arising from short-term use of low-dose HT, provided they do not have specific contraindications. HT may be unsuitable for some women, including those at increased risk of cardiovascular disease, increased risk of thromboembolic disease (such as those with obesity or a history of venous thrombosis) or increased risk of some types of cancer (such as breast cancer, in women with a uterus). The risk of endometrial cancer among women with a uterus taking oestrogen-only HT is well docu...
Source: Cochrane Database of Systematic Reviews - Category: Journals (General) Authors: Tags: Cochrane Database Syst Rev Source Type: research
By now, most people have been to a holiday party or two. Lots of food, lots of eggnog and other carb laden alcoholic beverages, and lots of grazing all day long on all the boxes of candy friends and business acquaintances sent to us. It's easy to gain the five pounds most people gain during the holidays, and in the process, raise your blood sugar or glucose levels too high. That's your body letting you know you have prediabetes (higher than normal but still below diabetes levels) or diabetes, and unless you take action soon, your body won't like it. Diabetes silently sneaks up on you and if untreated, slowly weakens your ...
Source: Healthy Living - The Huffington Post - Category: Consumer Health News Source Type: news
Abstract Modifiable lifestyle factors may reduce the risk of developing breast cancer. Obesity is associated particularly with post-menopausal breast cancer. Diet is important, and exercise equivalent to running for up to 8 hours each week reduces the risk of breast cancer, both in its own right and through reducing obesity. Alcohol consumption may be responsible for 5.8% of breast cancers in Australia and it is recommended to reduce this to two standard drinks per day. Drinking alcohol and smoking increases the risk for breast cancer and, therefore, it is important to quit tobacco smoking. Prolonged use of combin...
Source: Med J Aust - Category: Journals (General) Authors: Tags: Med J Aust Source Type: research
In this month’s article, I explore issues relating to the health of women in emerging markets. I will recommend that pharma companies wishing to maximize the opportunity in women’s health need to start from an understanding of how women are viewed by society in these markets and challenge awareness, attitudes and access barriers that can lead to their health outcomes being sub-optimal. As a starting point, it is necessary to establish a working definition of women’s health.  This isn’t as straightforward as it might seem, as women’s health can be considered at multiple levels.  The c...
Source: EyeForPharma - Category: Pharmaceuticals Authors: Source Type: news
The recent approval of Senshio®, 60mg ospemifene, for the indication treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women who are not candidates for local vaginal oestrogen therapy [1] is a valuable addition to the armamentarium for doctors to treat vulvo-vaginal atrophy. This is the first non-hormonal oral product to be licensed for this indication. Senshio® (60mg ospemifene) is a Selective Oestrogen Receptor Modulator (SERM). There are various SERMs available for different indications (treatment of breast cancer: tamoxifen and toremifene, treatment of osteoporosis:...
Source: Maturitas - Category: Primary Care Authors: Tags: LBN 20 Source Type: research
Background: Chemoprevention with anti-estrogens, such as tamoxifen, raloxifene, and aromatase inhibitors, has been shown to reduce breast cancer incidence in high-risk women; however, uptake remains low (
Source: Cancer Prevention Research - Category: Cancer & Oncology Authors: Tags: Decision Making: Oral Presentations - Proffered Abstracts Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Education | Epidemiology | Heart | Hormone Replacement Therapy | Hormones | Men | Menopause | Oral Cancer | Orthopaedics | Osteoporosis | Respiratory Medicine | Smokers | Spirometry | Study | Universities & Medical Training | Women